Hospital.Help

Basel – The alpha-synuclein antibody prasinezumab, which was unable to stop the progression of Parkinson’s disease in a randomized phase 2 study, could still have a disease-modifying effect in the long term. This is suggested by the results of an open follow-up study with a treatment period of up to 4 years published in Nature Medicine (2024; DOI: 10.1038/s41591-024-03270-6). So far there is no…